Prescription medicine
Colchicine and probenecid First approved as Colbenemid
Colchicine and probenecid (Colbenemid) is a prescription medicine with an FDA approval on record since 1961. FDA's NDC Directory lists it from 4 generic labelers, and pharmacies paid $0.830 per probenecid-colchicine tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the colchicine and probenecid FDA label on DailyMed (effective January 27, 2026, Rising Pharma Holdings, Inc.); the NDA 12383 record on Drugs@FDA; every colchicine and probenecid label on DailyMed.
Highlights of the record
FDA label of January 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageFor the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout.
Forms and strengths
- 500 mg / 0.5 mg
Tablet.
On the market
- Earliest approval on file
- July 27, 1961 Colbenemid, Merck; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 9 first April 7, 1975; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 4 of which 4 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.830 per tablet Probenecid-colchicine tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 102 through July 30, 2026
What is colchicine and probenecid used for?
From the label: indications and usageFor the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout.
Conditions named in the indications of colchicine and probenecid's FDA labels, with every medicine labeled for each:
From other colchicine and probenecid labelsGout: INDICATIONS & USAGE For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout.
FDA pharmacologic class: Alkaloid.
Source: FDA drug label (Probenecid and Colchicine), Rising Pharma Holdings, Inc., effective January 27, 2026 (SPL set 3d2a3d4f-38a3-4669-ad78-ab1d7aef4ec3), via openFDA; the full label on DailyMed
Is there a generic for colchicine and probenecid (Colbenemid)?
The FDA approved the first generic colchicine and probenecid on April 7, 1975. 9 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists colchicine and probenecid from 4 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1961 earliest approval on file
- 1975 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for colchicine and probenecid (Colbenemid)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.830 per Probenecid-colchicine tablet, down 8% from $0.905 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Probenecid-colchicine tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Probenecid-colchicine tablet | Generic | $0.830 per tablet | $24.91 | -8% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the colchicine and probenecid label say about other medicines?
The colchicine and probenecid label names 12 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acetaminophen | drug interactions | These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. |
| Indomethacin | drug interactions | These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. |
| Ketamine | drug interactions | In addition, ketamine and thiopental anesthesia were significantly prolonged in rats receiving probenecid. |
| Ketoprofen | drug interactions | These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. |
| Lorazepam | drug interactions | These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. |
| Meclofenamate | drug interactions | These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. |
| Methotrexate | drug interactions | In animals and in humans, probenecid has been reported to increase plasma concentrations of methotrexate (see WARNINGS ). |
| Naproxen | drug interactions | These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. |
| Pyrazinamide | drug interactions | The uricosuric action of probenecid is also antagonized by pyrazinamide. |
| Rifampin | drug interactions | These include agents such as indomethacin, acetaminophen, naproxen, ketoprofen, meclofenamate, lorazepam, and rifampin. |
| Sulindac | drug interactions | Probenecid given concomitantly with sulindac had only a slight effect on plasma sulfide levels, while plasma levels of sulindac and sulfone were increased. |
| Theophylline | drug interactions | Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. |
Source: FDA drug label (Probenecid and Colchicine), Rising Pharma Holdings, Inc., effective January 27, 2026 (SPL set 3d2a3d4f-38a3-4669-ad78-ab1d7aef4ec3), via openFDA; the full label on DailyMed
What do FAERS reports show for colchicine and probenecid?
The FDA Adverse Event Reporting System holds 102 reports that list colchicine and probenecid among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 24 are coded as a death and 54 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as colchicine and probenecid?
2 other medicines are given the same way (oral) and in the same FDA class as colchicine and probenecid or labeled mainly for the same use (gout), the same class first. Gout lists all 8 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Allopurinol | Gout | 42 labelers | $0.0315 per tablet 100 mg tablet | A presentation being discontinued |
| Febuxostat | Gout | 23 labelers | $0.191 per tablet 40 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Other alkaloids
- the pharmacologic class, with prices and generics
- Colchicine and probenecid side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other